Veach DR, Namavari M, Pillarsetty N, Santos EB, Beresten T, Lambek C, Punzalan BJ, Antczak C, Smith-Jones P, Djaballah H, Clarkson B, Larson SM. Synthesis and Biological evaluation of a Fluorine-18 derivative of Dasatinib.- Journal of Medicinal Chemistry, 50, (23), 5853-5857, 2007.

Wendel H G, de Stanchina E, Cepero E, Ray S, Emig M, Fridman JS, Veach DR, Bornmann WG, Clarkson B, McCombie WR, Kogan SC, Hochhaus A, and Lowe SW: Loss of p53 impedes the antileukemic response to BCR ABL inhibition. PNAS 103:7444 7449, 2006.

Azam M, Nardi V, Shakespeare WC, Metcalf III CA, Bohacek RS, Wang Y, Sundaramoorthi R, Sliz P, Veach DR, Bornmann WG, Clarkson B, Dalgarno DC, Sawyer TK, and Daley GQ: Activity of dual SRC ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. PNAS 103:9244 9249, 2006.

Liang X, Hajivandi M, Veach D, Wisniewski D, Clarkson B, Resh, MD, and Pope MR: Quantification of change in phosphorylation of BCR ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells. Proteomics August; 6 (16): 4554-64, 2006.

Wolff NC, Veach DR, Tong WP, Bornmann WG, Clarkson B, and Ilaria, RL Jr.: PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia. Blood 105:3995 4003, 2005.

von Bubnoff N, Veach DR, van der Kuip H, Aulitsky WE, Sanger J, Seipel P, Bornmann WG, Peschel C, Clarkson B, and Duyster J: A cell based screen for resistance of Bcr Abl positive leukemia identifies the mutation pattern for a PD166326, an alternative Abl kinase inhibitor. Blood 105:1652 1659, 2005.

Veach DR, Namavari M, Beresten T, Balatoni J, Minchenko M, Djaballah H, Finn RD, Clarkson B, Gelovani JG, Bornmann WG, and Larson SM: Synthesis and in vitro examination of [124I] , [125I] and [131I] 2 (4 iodophenylamino) pyrido [2,3 d] pyrimidin 7 one radiolabeled Abl kinase inhibitors. Nuclear Medicine and Biology 32:313 321, 2005.

Tipping AJ, Baluch S, Barnes DJ, Veach DR, Clarkson BM(sic), Bornmann WG, Mahon FX, Goldman JM, and Melo JV: Molecular Targets For Therapy (MTT): Efficacy of dual specific Bcr Abl and Src family kinase inhibitors in cells sensitive and resistant to imatinib mesylate. Leukemia 18 (8)1352 1356. 2004.

von Bubnoff N, Veach DR, Miller WT, Li W, Sänger J, Peschel C, Bornmann WG, Clarkson B, Duyster J. Inhibition of wild-type and mutant Bcr-Abl by pyrido- pyrimidine-type small molecule kinase inhibitors. Cancer Res. 2003;63:6395-6404.

Strife A, Wisniewski D, Liu C, Lambek CL, Darzynkiewicz Z, Silver RT, and Clarkson B. Direct evidence that Bcr-Abl tyrosine kinase activity disrupts normal synergistic interactions between kit ligand and cytokines in primary primitive progenitor cells. Mol Cancer Res. 2003;1:176-185.

Netzer WJ, Dou F, Cai D, Veach D, Jean S, Li Y, Bornmann WG, Clarkson B, Xu H, Greengard P. Gleevec inhibits beta-amyloid production but not Notch cleavage. Proc Natl Acad Sci USA. 2003;100:12444-12449.

Nagar B, Hantschel O, Young MA, Scheffzek K, Veach D, Bornmann W, Clarkson B, Superti-Furga G, Kuriyan J. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell. 2003;112:859-871.

Clarkson B, Strife A, Wisniewski D, Lambek CL, Liu C. Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies. Leukemia. 2003;17:1211-1262.

Wisniewski D, Lambek C, Liu C, Strife A, Veach D, Nagar B, Young MA, Schindler T, Bornmann W, Bertino JR, Kuriyan J, Clarkson B. Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Res. 2002;62:4244-4255.

Nagar B, Bornmann W, Pellicena P, Schindler T, Veach D, Miller TW, Clarkson B, Kuriyan J. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 2002;62:4236-4243.

Liang X, Wisniewski D, Strife A, Shivakrupa, Clarkson B and Resh MD. Phosphatidylinositol 3-kinase and Src family kinases are required for phosphorylation and membrane recruitment of Dok-1 in c-kit signaling. J Biol Chem. 277:13732-13738, 2002.

Clarkson B. Chronic myelogenous leukemia: Prognosis and current status of treatment. In: Joseph R. Bertino, ed. Encyclopedia of Cancer, 2nd edition. California: Academic Press; 2002:519-524.

Clarkson B. Chronic myelogenous leukemia: Etiology, incidence, and clinical features. In: Joseph R. Bertino, ed. Encyclopedia of Cancer, 2nd edition. California: Academic Press; 2002:505-518.

Schindler T, Bornmann W, Pellicena P, Miller T, Clarkson B and Kuriyan J: Structural mechanism for STƒ¡ 571 inhibition of Abelson tyrosine kinase. Science 289:1938 1942, 2000.